NCBiotech News

Cell Microsystems, a provider of tools and solutions for sorting and isolating single cells, has been awarded a $1.5 million federal grant to develop a system for imaging thousands of single cells and preparing them for genomic analysis.

Durham-based Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).

Craft Technologies, a contract laboratory in Wilson that analyzes nutrients, vitamins, carotenoids, bioflavonoids and phytochemicals, has been acquired by the food division of Eurofins North America for undisclosed terms.

If you’re among the thousands of pharmaceutical manufacturing workers in six Southeastern states, you can escape the admission fee for the 25th annual conference of the International Society for Pharmaceutical Engineering’s Carolina-South Atlantic chapter March 13 in Raleigh.

Twenty-six life science companies from across North Carolina will present their stories at the Council for Entrepreneurial Development’s 27th annual Life Science Conference Feb. 27-28 at the Raleigh Convention Center.

With their $7.4 billion merger complete, Raleigh-based INC Research and InVentiv have rebranded as Syneos Health Inc.

NeuroTronik Inc. of Durham has closed on $23.1 million in Series B preferred stock financing to advance its therapy for treating acute heart failure in hospitals.

The Durham-based venture capital firm Hatteras Venture Partners was a major investor, along with lead investor Boston Scientific Group and others including Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital and Sovereign’s Capital.

To those who think biotechnology in North Carolina is an urban industry suited only for the Research Triangle, Piedmont Triad or Greater Charlotte regions, Mark Phillips has some eye-opening data that will nix that perception.

Fervent Pharmaceuticals of Greenville has successfully submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for FP-101, its proprietary lead drug candidate for treating menopause symptoms.

Fresenius Kabi will expand its drug-manufacturing operations in Wilson, potentially bringing at least 445 new jobs over five years and $100 million in investment.

North Carolina is the nation’s best state for business in 2017, according to the business magazine Forbes.

Corning, the global materials science company known for its glass and ceramics, will create 428 jobs over three years in North Carolina by investing $275 million in a manufacturing plant expansion in Durham County and a new warehouse in Edgecombe County.

RedHill Biopharma, an Israeli company with U.S. headquarters in Raleigh, has received orphan drug designation for its pancreatic drug candidate from the U.S. Food and Drug Administration.

Durham-based Baebies Inc., a developer of products and services for newborn screening and pediatric testing, has closed on $10 m

The University of North Carolina, a powerhouse in gene therapy research, has signed exclusive licensing agreements with a New York City biotechnology company for three preclinical gene therapies that could treat an eye disease, certain muscular dystrophies and rejection of corneal transplants.